<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ArticleSet PUBLIC "-//NLM//DTD PubMed 2.7//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/in/PubMed.dtd">
<ArticleSet>
<Article>
<Journal>
				<PublisherName>West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter.</PublisherName>
				<JournalTitle>Asian Pacific Journal of Cancer Prevention</JournalTitle>
				<Issn>1513-7368</Issn>
				<Volume>16</Volume>
				<Issue>13</Issue>
				<PubDate PubStatus="epublish">
					<Year>2015</Year>
					<Month>12</Month>
					<Day>01</Day>
				</PubDate>
			</Journal>
<ArticleTitle>Individualized Chemotherapy for Metastatic Gastric Cancer: Retrospective Data from a University Hospital in Brazil</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>5289</FirstPage>
			<LastPage>5296</LastPage>
			<ELocationID EIdType="pii">31250</ELocationID>
			
			
			<Language>EN</Language>
<AuthorList>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>1970</Year>
					<Month>01</Month>
					<Day>01</Day>
				</PubDate>
			</History>
		<Abstract>&lt;b&gt;Background:&lt;/b&gt; Despite the decreased incidence, gastric cancer is still a frequent cause of cancer related death.The 1st line 2 or 3 drugs regimen is still a debatable issue. HER2 targeted therapy has emerged as the standard ofcare, but it is unavailable in the Brazilian Public Health System. The end-point of this trial was overall survival(OS) in patients with metastatic gastric cancer treated in a public university hospital in Brazil. The secondaryend-points were efficacy and safety of regimens with 2 (F+P) or 3 (EOX) drugs to develop an institutionalguideline to facilitate optimal treatments. Materials and &lt;br/&gt;&lt;b&gt;Methods&lt;/b&gt;: In this retrospective study, 1st line regimenswere evaluated for OS and PFS stratified by age and ECOG using Cox regression. &lt;br/&gt;&lt;b&gt;Results&lt;/b&gt;: 47 patients weretreated over the last 3 years. In 1st line, 29 were treated with F+P (mean 59.3 years, 34.5% ECOG 2 and a meanof 5.69 cycles) and 16 with EOX (mean 47 years, 18.8% ECOG 2 and a mean of 5.44 cycles). The median OSwas 13.8 months (95%CI 10.7-16.9). Response was evaluated in 40 cases and was 64.3% for EOX and 37.5% forF+P (p=0.25). The median PFS was 9.5 months for EOX and 5.6 months for F+P (HR 0.85, 95%CI 0.41-1.74).However, among patients with ECOG 2 mPFS was 3.70 vs 5.40 months, respectively (p=0.86). Regimens showedsimilar manageable adverse events. A total of 34 patients suffered progression and 14 received 2nd line therapy.Diffuse histology (HR 1.89, 95%CI 1.22-2.88), achieving 2nd line (HR: 0.25, 95%CI 0.11-0.58) and treatmentresponse (HR 0.23, 95%CI 0.12-0.47) were OS prognostic factors. &lt;br/&gt;&lt;b&gt;Conclusions&lt;/b&gt;: Patients treated in our hospitalhad outcomes compatible with the literature. The regimen choice should be related to patient features. Secondline treatment should be considered.</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">Gastric cancer</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Chemotherapy</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Metastatic</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">treatment</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://journal.waocp.org/article_31250_77e0d8e74a0f6b67fb6b12e11d77120d.pdf</ArchiveCopySource>
</Article>
</ArticleSet>
